Protecting the Embryo from X-Rated Drugs

Publisher Website
Google Scholar
Abstract
No one who attended the hearings on isotretinoin at the Maryland headquarters of the Food and Drug Administration (FDA) in April 1988 could have failed to notice that the physicians present were split into two camps. On one side sat the dermatologists. They showed slides of patients with disfiguring acne, some of whom had threatened to commit suicide. On the other side sat the pediatricians. They showed slides of patients ravaged by prenatal exposure to isotretinoin, now profoundly handicapped physically and mentally. The first group pleaded that isotretinoin be allowed to remain on the market, and the second group that . . .

This publication has 3 references indexed in Scilit: